Dáil Éireann Debate, Wednesday - 1 June 2016
190. Deputy Thomas P. Broughan asked the Minister for Health the savings from a reduction in the cost of branded medicines to the average European Union level; and if he will make a statement on the matter. [13961/16]
View answerIt is not feasible to provide a robust estimate of savings from a reduction in the price of branded medicines to the average European Union level, as the price of each branded medicine would need to be assessed and compared with pricing data from all of the other member states. In addition, I would draw the Deputy's attention to the Joint Committee on Health and Children Report on the Cost of Prescription Drugs in Ireland published in October 2015 and in particular their view that consideration should be given as to whether the average price is the most cost-effective option in setting drug prices in Ireland.
